TABLE 3

In vitro effects of nicotine on lung cancer under nonphysiologic conditions and/or with nonpharmacological concentrations of nicotine

Lung Cancer Cell LineNicotineDuration of TreatmentSerum ConcentrationCellular Response (Assay)Result (Relative to Control)Reference
H460, H1570.01–7 days10%Viability (MTT)H460: 5% increase (10, 100 μM), 5% decrease (1 mM)Chen et al. (2002)
1 mMH157: 5% decrease (10 μM), 5% increase (0.1–1 mM)
201T10 μM48 h10%Viability (MTS)No effectCarlisle et al. (2007)
H46010 nM, 0.01–1 mM5 days10%Viability (Cell Titer-Glo)12.5%–50% increaseZheng et al. (2007)
(10 nM, 10–100 μM),* no effect (1 mM)
A549, H12991 nM to 10 mM72 hNot indicatedViability (MTT)A549: 5%–18% increase (1 nM to 10 μM), no effect (100 μM), 5%–40% decrease (1–10 mM)Puliyappadamba et al. (2010)
H1299: 10%–30% increase (1–100 nM), no effect (1–100 μM),
40%–80% decrease (1–10 mM)
H4462.5–15 μM12–72 h10%Viability (MTT)0%–85% decreaseZeng et al. (2012)
A5490.01, 10 μM24 h10%Viability (MTS)No effect (0.01 μM),Gao et al. (2016)
75% decrease (10 μM)*
A549, H197510 nM to 100 μM48 h0% for 72 h, then treatedViability (MTS)A549: 12.5% increase (50 nM to 100 μM),* H1975: no effectMucchietto et al. (2017)
Proliferation (cell counting)A549: 33%–66% increase,* H1975: no effect
A5490.5–10 μM72 h0%Growth (BrdU)0%–9% increaseJarzynka et al. (2006)
Line11 μM18 h0% for 72 h, then treatedGrowth (BrdU)180% increaseDavis et al. (2009)
LKR1 μM24 h0.2% for 24 h, then treatedGrowth ([3H]-thymidine)200% increaseNishioka et al. (2010)
A549, H12991 nM to 100 μM24 hNot indicatedGrowth ([3H]-thymidine)5%–20% increase (1 nM to 1 μM),Puliyappadamba et al. (2010)
5%–20% decrease (10–100 μM)
A5491 μM18 h0% for 36 h, then treatedGrowth (BrdU)150% increase*Dasgupta et al. (2011)
A549, H16501 μM18 h0% for 24 h, then treatedGrowth (BrdU)175%–180% increasePillai et al. (2011)
24 hInvasion (Boyden)90%–100% increase
A549, H16501 μM18 h0% for 24 h, then treatedGrowth (BrdU)75%, 100% increaseNair et al. (2014)
24 hInvasion (Boyden)75%, 150% increase
LLC1 pM to 100 μMNot indicated0.1%Proliferation (cell counting)No effectHeeschen et al. (2001)
H157, H1703100 nM3 daysa0.1%Proliferation (cell counting)50%–95% increase*Tsurutani et al. (2005)
H129910 nMPreviously treated for 72 h, then seededNot indicatedProliferation (colony formation)150% increasePuliyappadamba et al. (2010)
A5490.01–10 μM18 h0% (before and during treatment)Invasion (Boyden)10% decrease (10 nM), 50%–160% increase (0.1–1 μM), 90% increase (10 μM)Dasgupta et al. (2009)
24 h0% (during treatment)Migration (wound healing)10%–100% increase (0.01–1 μM), 25% increase (10 μM)
N417500 μMPreviously treated for 7 days, then seeded10%Proliferation (colony formation)130% increase*Martínez-García et al. (2010)
0.5%Migration (Transwell)55% increase*
A549, H12990.1–1 μM36 h0% for 24 h, treated, then seededProliferation (cell counting)50%–200% increase*Liu et al. (2015)
Migration (wound healing)30% increase*
Invasion (Transwell)20% increase*
A549, H1650, H1975, H23, H3581 μM24 h0% for 36 h, then treatedInvasion (Boyden)120%–430% increase*Pillai et al. (2015)
A549, H12991 μM,48 h0% for 12 h, then treatedViability (CCK-8)25%, 40% increase*Gong et al. (2014)
10 nM48 hInvasion (Transwell)75% increase*
48 hMigration (wound healing)25%, 30% increase*
72 h
A549, H460, LLC, T15, 10 μM24 h10%Viability (MTS, MTT)No effectKyte et al. (2018)
A549, H4601 μM48–96 h0%–5%Viability (MTS, MTT)A549: no effect, H460: 25% increase with 0% serum at 96 h*
A5495 μM48 h10%Invasion (QCM)950% increase*Zhang et al. (2007)
5, 10 μM16 hAngiogenesis (HIF-1α)1000%, 1100% increase*
5, 10 μM16 hAngiogenesis (VEGF)130%, 170% increase*
A549, H1299, H197510, 50 μM24 h10%Viability (MTT)A549: 40% increase (10 μM),* no effect (50 μM)Ma et al. (2014)
H1299: 13%, 14% increase, H1975: 65% increase (10 μM),* 40% increase (50 μM)
A5495 μM16 hAngiogenesis (HIF-1α)25% increase
A5495 μM16 hAngiogenesis (VEGF)150% increase
A5495 μM36 h10%Invasion (Transwell)230% increase*Shi et al. (2015)
16 hAngiogenesis (VEGF protein, mRNA)25% increase,* 700% increase*
16 hAngiogenesis (HIF-1α mRNA)100% increase*
  • BrdU, bromodeoxyuridine; CCK-8, cell counting kit-8; HIF-1α, hypoxia-inducible factor 1-α; LLC, Lewis lung carcinoma; MTS, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; QCM, QCM (TM) collagen-based cell invasion assay; T1, primary human lung carcinoma; VEGF, vascular endothelial growth factor.

  • a Nicotine was replaced every 24 h.

  • * Statistically significant.

  • Statistical significance not indicated.